Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies
Archives of Microbiology · 2026-07 · 208 (7)
DOI: 10.1007/s00203-026-04839-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Microbiology, online erschienen am 24.04.2026. Verfasst von Sheeba Sawant und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science and Engineering, University of Wolverhampton, Wulfruna St, Wolverhampton, WV1 1LY, UK. Hauptthemen laut MEDLINE: Pseudomonas Infections, Pseudomonas aeruginosa. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 207 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pseudomonas aeruginosa is recognized as a critical-priority pathogen due to its major role in healthcare-associated infections (HAIs) and the rapid global rise of multidrug resistance. It is responsible for approximately 7.1–7.3% of HAIs worldwide and up to 23% of intensive care unit infections, specifically ventilator-associated pneumonia, where mortality can reach 32–42.8%. In chronic lung diseases, especially cystic fibrosis, P. aeruginosa commonly becomes the dominant pathogen in adulthood and contributes to progressive lung function decline. A major factor supporting long-term survival is biofilm formation, which can increase antimicrobial tolerance by up to 1000-fold compared with free-living bacteria. Virulence is further regulated through coordinated production of phenazines, rhamnolipids, exopolysaccharides, and quorum sensing signalling systems. The toxin pyocyanin, produced by 90–95% of clinical isolates, damages host tissues by disrupting cellular respiration, impairing ciliary activity, disturbing calcium balance, and promoting neutrophil apoptosis. During chronic infection, host defence mechanisms, including epithelial barriers, mucociliary clearance (~90% removal of inhaled particles), antimicrobial peptides, and immune cell responses, become less effective, while biofilms promote persistent inflammation and poor bacterial clearance. Increasing multidrug and carbapenem resistance (up to 47.6% in Europe and 32.8% in Asia) is driving interest in alternative therapies, including anti virulence agents, biofilm-disrupting enzymes, nanoparticles, bacteriophage therapy, and host-directed approaches targeting excessive inflammatory responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Science and Engineering, University of Wolverhampton, Wulfruna St, Wolverhampton, WV1 1LY, UK.
- Dentistry, School of Health Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham, B5 7EG, UK. a.s.rahman@bham.ac.uk.
Zitieren
APA
Sawant, S., Shaikh, S., Baldwin, T. C., Karakoula, A., & Rahman, A. (2026). Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies. Archives of Microbiology, 208(7). https://doi.org/10.1007/s00203-026-04839-0
Vancouver
Sawant S, Shaikh S, Baldwin TC, Karakoula A, Rahman A. Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies. Archives of Microbiology. 2026;208(7). doi:10.1007/s00203-026-04839-0
BibTeX
@article{Sawant2026,
author = {Sawant, Sheeba and Shaikh, Safura and Baldwin, Timothy C and Karakoula, Aikaterini and Rahman, Ayesha},
title = {Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies},
journal = {Archives of Microbiology},
year = {2026},
volume = {208},
number = {7},
doi = {10.1007/s00203-026-04839-0}
}
EUVIMED